ADMA Biologics Inc (ADMA)

Operating profit margin

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Operating income (ttm)	US$ in thousands	114,893	83,940	44,266	21,632	1,340	-16,662	-25,364	-39,366	-46,498	-51,618	-58,024	-58,373	-62,402	-61,766	-63,309	-64,915	-55,522	-50,771	-44,986	-41,424
Revenue (ttm)	US$ in thousands	382,809	330,245	283,177	258,216	234,293	208,108	181,890	154,079	130,481	110,072	93,998	80,944	68,517	58,112	48,069	42,220	40,301	37,248	36,021	29,350
Operating profit margin		30.01%	25.42%	15.63%	8.38%	0.57%	-8.01%	-13.94%	-25.55%	-35.64%	-46.89%	-61.73%	-72.12%	-91.08%	-106.29%	-131.70%	-153.75%	-137.77%	-136.31%	-124.89%	-141.14%

September 30, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $114,893K ÷ $382,809K
= 30.01%

The operating profit margin of ADMA Biologics Inc has shown a fluctuating trend over the past few quarters. The margin has improved significantly from negative figures in 2021 to positive figures in 2024. There was a notable improvement in the operating profit margin from Dec 31, 2023, to Sep 30, 2024, indicating that the company has been more effective in controlling its operating expenses and generating operating profits.

Despite the positive trend in recent quarters, the operating profit margin remains relatively volatile, as seen in the significant fluctuations over the observed period. It is important for ADMA Biologics Inc to sustain and potentially improve its operating profit margin to ensure sustainable profitability and operational efficiency. An operating profit margin above 20% is generally considered healthy in the biopharmaceutical industry, so the company should strive to maintain or exceed this level to demonstrate strong operational performance and generate value for its stakeholders.